A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis

INFECTIOUS DISEASES RESEARCH INSTITUTE,0 个研究点目标入组 46 人开始时间: 2009年4月6日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 46

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65（—）
性别: All

入选标准

•Males and females ≥ 12 years and < 70 years of age. In the first stage of the study, only patients aged ≥ 18 years and < 70 years will be enrolled. In the second stage, enrollment will also include adolescent patients aged ≥ 12 - < 18 years.
•Must have a clinical diagnosis of cutaneous leishmaniasis confirmed by positive identification of Leishmania parasite and identification of L. peruviana by PCR.
•Lesions must be clear of any superinfection prior to enrollment.
•Female patients of childbearing age must have a negative serum pregnancy test at screening, a negative urine pregnancy test within 24 hours before the first vaccination or initiation of chemotherapy, must not be breast-feeding, and are required to use adequate contraception through Day 84 of the study. These precautions are necessary due to unknown effects that LEISH-F2 + MPL SE, sodium stibogluconate might have in a fetus or newborn infant.
•The following laboratory blood tests must have values within the normal ranges at screening: sodium, potassium, urea, total bilirubin, ALT, AST, glucose, creatinine, alkaline phosphatase, total WBC count and platelet count. Hemoglobin may exceed the ULN since patients reside in the Andes at very high altitude (up to 20 g/dL)
•The following serology tests must be negative at screening: HIV-1/2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All patients (or their parents) will receive HIV-related counseling prior to testing. Patients with positive HIV test results will be referred for counseling and treatment as appropriate.
•Potential study patients (or their guardians) must give written informed consent, be willing to be housed in Lima for a minimum of 20 days and up to 63 days, able to attend all required follow-up visits, have a permanent address, and be reachable by study site personnel.

排除标准

•Infection with species other than L.peruviana as confirmed by PCR.
•Presence of eleven or more active cutaneous leishmaniasis lesions.
•The diameter of the ulcerated area of any single lesion is >60 mm.
•Presence of lesions with superinfection at time of enrollment.
•History of mucocutaneous leishmaniasis or diagnosis of mucocutaneous leishmaniasis at screening.
•History of previous exposure to Leishmania vaccines.
•Known use of injected or oral corticosteroids within 6 weeks prior to the first vaccination or initiation of chemotherapy.
•Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first vaccination or initiation of chemotherapy.
•History of autoimmune disease or other causes of immunosuppressive states.
•History or evidence of any acute or chronic illness that, in the opinion of the study clinician, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Patients presenting with concomitant illness will be referred for standard clinical care).
•History of use of any medication that, in the opinion of the study clinician, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.
•History of significant psychiatric illness.
•Drug addiction including alcohol abuse.
•Patients with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.
•Patients who are unlikely to cooperate with the requirements of the study protocol.
•ECG with evidence of ventricular arrythmias ≥ 4 extra systoles per minute.
•Known allergy or contraindication to chemotherapy (e.g., known reaction to pentavalent antimonials, cardiopathy, myocarditis).

研究者

发起方

INFECTIOUS DISEASES RESEARCH INSTITUTE,

相似试验

尚未招募

2 期

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic AdenocarcinomaPancreas cancerLocally Advanced Pancreatic Adenocarcinoma1001567410017991

NL-OMON56480AIM ImmunoTech Inc.30

进行中（未招募）

1 期

EUCTR2019-003117-33-ITMILLENNIUM PHARMACEUTICALS, INC.150

进行中（未招募）

1 期

A Clinical Study to Compare the Effectiveness and Safety of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyAcute Myeloid Leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: LLTClassification code 10024330Term: Leukemia acuteSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10024348Term: Leukemia myelogenousSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-003117-33-PLMillennium Pharmaceuticals, Inc.150

进行中（未招募）

1 期

EUCTR2019-003117-33-FRTakeda Development Center Americas, Inc.150

进行中（未招募）

1 期

A study evaluating the clinical benefit of Cemiplimab versus Cemiplimab in combination with RP1 in patients with skin cancerAdvanced Cutaneous Squamous Cell CarcinomaMedDRA version: 21.1Level: PTClassification code 10077314Term: Skin squamous cell carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-003964-30-PLReplimune, Inc.230